Realm Therapeutics - Block listing Interim Review

February 18, 2019
window.NREUM||(NREUM={});NREUM.info = {"beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"6415801d43","applicationID":"186842935","transactionName":"NVFUYEIHWkEDARFRXgwbd2dgSU9EBxAWUV4MSRlPUwpdVwwWLHxMTXlXRlsDQB0sBxJLHhl9ckkfJFtWG00eW14MQFNaRC9wTw==","queueTime":0,"applicationTime":12,"agent":"","atts":""}window.NREUM||(NREUM={}),__nr_require=function(e,n,t){function r(t){if(!n[t]){var o=n[t]={exports:{}};e[t][0].call(o.exports,function(n){var o=e[t][1][n];return r(o||n)},o,o.exports)}return n[t].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o var w=window;if(w.performance||w.mozPerformance||w.msPerformance||w.webkitPerformance){var d=document;AKSB=w.AKSB||{},AKSB.q=AKSB.q||[],AKSB.mark=AKSB.mark||function(e,_){AKSB.q.push(["mark",e,_||(new Date).getTime()])},AKSB.measure=AKSB.measure||function(e,_,t){AKSB.q.push(["measure",e,_,t||(new Date).getTime()])},AKSB.done=AKSB.done||function(e){AKSB.q.push(["done",e])},AKSB.mark("firstbyte",(new Date).getTime()),AKSB.prof={custid:"793678",ustr:"",originlat:"0",clientrtt:"1",ghostip:"104.112.235.156",ipv6:false,pct:"10",clientip:"35.173.227.30",requestid:"a3300b0b",region:"26162",protocol:"",blver:14,akM:"a",akN:"ae",akTT:"O",akTX:"1",akTI:"a3300b0b",ai:"501146",ra:"false",pmgn:"",pmgi:"",pmp:"",qc:""},function(e){var _=d.createElement("script");_.async="async",_.src=e;var t=d.getElementsByTagName("script"),t=t[t.length-1];t.parentNode.insertBefore(_,t)}(("https:"===d.location.protocol?"https:":"http:")+"//ds-aksb-a.akamaihd.net/aksb.min.js")}
RNS Number : 2001Q
Realm Therapeutics PLC
18 February 2019
 

Realm Therapeutics plc

Block Listing Interim Review

 

Pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies Realm Therapeutics plc makes the following update on its block listing:

 

Date: 18 February 2019

 

Name of applicant:

Realm Therapeutics plc

Name of scheme:

Executive Omnibus Incentive Plan

Warrants

Figures for all schemes relate to ordinary shares

of 10 pence each

Period of return:

From: 18 August 2018 To: 15 February 2019

Balance of unallotted securities under scheme(s) from previous return:

2,055,362

21,257,021

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Nil

Nil

Less:  Number of securities issued/allotted under scheme(s) during period:

Nil

Nil

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

2,055,362

21,257,021

 

 

Number and class of securities originally admitted:

 

* these securities have been adjusted for a 1 for 10 share consolidation which took effect on 2 July 2010

*20,000 and

*378,423 + *32,000 and 200,000

*196,087 and

*21,108

Dates of Admission:

 

7 August 2006 and 31 August 2007 and 15 August 2012

7 August 2006 and

31 August 2007

Name of contact:

Marella Thorell, Company Secretary

Telephone number of contact:

+1 484-321-2749

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRGIGDDSXBBGCU

Search Investor Relations